SCHEMBL19609150

SCHEMBL19609150

COC(=O)c1ccc(/C=C/C(=O)N2CCC(CO)CC2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR183 P32249 7/20 0.61
▸ NPC1 O15118 4/20 0.54
▸ RAB9A P51151 4/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ SMN1; SMN2 Q16637 3/20 0.53
▸ LMNA P02545 3/20 0.52
▸ KDM4E B2RXH2 1/20 0.52
▸ MAPT P10636 1/20 0.52
▸ GAA P10253 3/20 0.51
▸ GRIN2D O15399 1/20 0.50
▸ GRIN3B O60391 1/20 0.50
▸ GRIN1 Q05586 1/20 0.50
▸ GRIN2A Q12879 1/20 0.50
▸ GRIN2B Q13224 1/20 0.50
▸ GRIN2C Q14957 1/20 0.50
▸ GRIN3A Q8TCU5 1/20 0.50
▸ HPGD P15428 1/20 0.48
▸ KDM1A O60341 3/20 0.48
▸ HDAC6 Q9UBN7 3/20 0.48
▸ KCNH2 Q12809 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28632807 0.85 LMNA (0.59) GPR183NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL28632808 0.85 LMNA (0.59) GPR183NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL19609151 0.84 GPR183 (0.62) GPR183NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL20866601 0.81 GPR183 (0.59) GPR183NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL12606900 0.80 LMNA (0.75) GPR183NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL19609094 0.79 ALDH1A1 (0.54) RAB9AALDH1A1SMN1; SMN2KDM4EMAPT
SCHEMBL15862146 0.77 MEN1 (0.55) NPC1ALDH1A1SMN1; SMN2MAPT
SCHEMBL28647040 0.76 GPR183 (0.44) GPR183NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL28647041 0.76 GPR183 (0.44) GPR183NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL7138273 0.75 ALDH1A1 (0.58) NPC1RAB9AALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479797-B2 Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors Jubilant Epicore LLC (US) 2025-11-25 — — US disclosed
EP-3455204-B1 CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS Jubilant Epicore LLC (US) 2025-10-29 — — EP disclosed
US-20220281815-A1 CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS Jubilant Epicore LLC 2022-09-08 — — US disclosed
US-11352322-B2 Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors Jubilant Epicore LLC (US) 2022-06-07 — — US disclosed
US-11352322-B2 Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors Jubilant Epicore LLC (US) 2022-06-07 — — US disclosed
CN-109153636-B Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors 朱比连特埃皮科尔有限责任公司 2021-10-22 — — CN disclosed
US-20200308110-A1 CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS Jubilant Epicore LLC 2020-10-01 — — US disclosed
WO-2017195216-A1 CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2017-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200308110-A1 CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS HDAC1, HDAC11, HDAC2 GPR183 2069/4885NPC1 301/4885RAB9A 2151/4885
US-11352322-B2 Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors HDAC1, HDAC11, HDAC2 GPR183 2069/4885NPC1 301/4885RAB9A 2151/4885
US-12479797-B2 Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors HDAC1, HDAC11, HDAC2 GPR183 2514/4885NPC1 297/4885RAB9A 1828/4885
US-20220281815-A1 CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS HDAC1, HDAC11, HDAC2 GPR183 2514/4885NPC1 297/4885RAB9A 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback